Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director
March 30 2021 - 8:00AM
The Board of Directors of Royalty Pharma plc (Nasdaq: RPRX) today
announced that the independent directors of the Board have
unanimously appointed Henry A. Fernandez as Lead Independent
Director. Mr. Fernandez is Chairman and Chief Executive Officer of
MSCI Inc. Mr. Fernandez will continue to serve on the Audit
Committee of Royalty Pharma plc.
“We are further strengthening the governance of Royalty Pharma
with this new key role," stated Pablo Legorreta, founder, CEO and
Chairman of Royalty Pharma. “Henry has a record of exceptional
leadership having led MSCI from a nascent index business to a
leading global provider of critical decision support tools for the
investment community. Henry has demonstrated tremendous business
acumen, a strong entrepreneurial spirit, unwavering integrity and a
clear focus on corporate responsibility. During his tenure at MSCI,
he has delivered significant value creation for all stakeholders.
Royalty Pharma will benefit greatly from Henry’s extensive
experience as we continue to build upon our unique leadership
position at the heart of funding biopharma innovation to improve
the lives of patients globally," Legorreta added.
“I am honored to be selected for this Board role,” said Henry A.
Fernandez. “I have observed the high caliber of the people at
Royalty Pharma and the strength of the business model as a longtime
shareholder and as a Board member since August 2020. I look forward
to providing strong independent oversight as Lead Independent
Director.”
About Henry A. Fernandez
Henry A. Fernandez has served as Director and Chairman of MSCI
Inc. since 2007 and as Chief Executive Officer since 1998. Before
leading MSCI’s transition to becoming a fully independent, public
company in 2007, he was a Managing Director at Morgan Stanley from
1983 to 1991 and from 1994 to 2007, where he worked in emerging
markets product strategy, equity derivative sales and trading,
mergers and acquisitions, worldwide corporate finance and mortgage
finance for U.S. financial institutions. Mr. Fernandez serves on
the Board of Trustees for Stanford University as well as Memorial
Sloan Kettering Cancer Center. Mr. Fernandez holds a Bachelor of
Arts in economics from Georgetown University, an M.B.A. from the
Stanford University Graduate School of Business and pursued
doctoral studies in economics at Princeton University.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’
Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and
five development-stage product candidates. For more information,
visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6772ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024